# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sonny Liston (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX007-SYN
- Date: 2026-07-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Malcolm Achebe-Whitford, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week review of blood pressure and drinking. **S**

## History of present illness

Sonny Liston returns four weeks after starting amlodipine 5 mg and valsartan 160 mg. He has taken it every morning and can say what it is for and when to take it. He did not send home readings for the first two weeks: the clinic had asked him to photograph the monitor and send the picture, and the steps on the phone were confusing. After a nurse called him in the third week he began reading the numbers out on the clinic voice line; the last seven mornings average 134/84 mmHg. No dizziness or ankle swelling. Drinking is down to about 15 drinks a week, but he still has five or six on Saturday nights and finds he cannot stop once he starts; he asks for the medicine he was told about. No thoughts of suicide. **S**

| Element | Detail |
|---|---|
| Home readings | Average 134/84 mmHg over the last seven mornings |
| Potassium and creatinine | 4.4 mmol/L and 1.1 mg/dL |
| AUDIT-C | 7 |
| Teach-back | Correct with the picture card |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Neurological | Negative | No dizziness or headaches |
| Gastrointestinal | Negative | No abdominal pain, nausea or yellowing |
| Psychiatric | Negative | Mood all right; no thoughts of suicide |

4 systems reviewed. **S**

## Current medications

- Amlodipine 10 mg and valsartan 160 mg combined oral tablet, one tablet each morning **S**
- Naltrexone 50 mg oral tablet, one tablet each morning **S**

## Allergies

- No known allergy **S**

## Objective

BP 136/86 mmHg; pulse 58 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 98 kg; BMI 28.6 kg/m². All vital signs are synthetic.

Potassium: 4.4 mmol/L; Creatinine: 1.1 mg/dL; eGFR (CKD-EPI 2021, race-free): 89 mL/min/1.73 m²; AUDIT-C: 7. All results are synthetic.

## Change since baseline

- Potassium: 4.1 mmol/L at baseline, 4.4 mmol/L at this visit **S**
- Creatinine: 1.1 mg/dL at baseline, 1.1 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021, race-free): 89 mL/min/1.73 m² at baseline, 89 mL/min/1.73 m² at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 136/86 mmHg (average of two); pulse 58; weight 98.0 kg |
| Cardiovascular | Regular rhythm; no edema |
| Abdomen | Liver not enlarged; no tenderness |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hypertension, stage 2** (I10). Better but above the goal of under 130/80 mmHg in the clinic and at home; potassium and creatinine unchanged on valsartan. **S**
   - Raise to amlodipine 10 mg and valsartan 160 mg in one tablet each morning; new picture card.
   - Home readings each morning by voice message.
   - Still no bouts until controlled.
2. **Alcohol use disorder, moderate** (F10.20). Progress, with loss of control on weekend nights; he chose naltrexone after the options were explained again. Liver tests at intake were well below the level that would rule it out, and he takes no opioids. **S**
   - Naltrexone 50 mg each morning.
   - A wallet card saying he takes naltrexone, which blocks opioid pain medicines, for any emergency.
   - Liver tests in about two months.
   - Keep the tally card and his drinking goal.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Office blood pressure (seated, large cuff, average of two readings), weight and BMI, heart sounds | Every visit | Completed today | 136/86 mmHg; weight 98.0 kg |
| Examination | Out-of-office blood pressure (ambulatory or home monitoring) | At diagnosis and after each treatment change | Deferred | Deviation: home readings were asked for each morning from the start of treatment but none arrived for two weeks, because the photo-upload steps were not usable for him and teach-back had not covered them. Office and later home readings agree, so no harm is known. Corrective action: readings by voice message, shown with teach-back by the nurse; seven readings in the last week averaged 134/84 mmHg |
| Laboratory | Potassium, creatinine and eGFR | Baseline; two to four weeks after starting an ARB; then every six months on an ARB | Completed today | Potassium 4.4 mmol/L, creatinine 1.1 mg/dL, eGFR 89, four weeks after starting valsartan; next in about six months |
| Laboratory | Lipids, glucose or A1c, urine albumin-to-creatinine ratio, TSH | At diagnosis, then yearly (TSH at diagnosis) | Up to date | Done at intake; next yearly |
| Imaging | Echocardiogram | At diagnosis for stage 2 hypertension or suspected LVH; repeat as indicated | Up to date | Mild LVH at two weeks; repeat in about a year to look for regression with control |
| Medication safety | Antihypertensive tolerance (ankle edema, dizziness) and adherence by teach-back | Each follow-up and each dose change | Completed today | No dizziness or edema on 5/160 mg; teach-back correct; dose raised today with a new picture card |
| Referral | Fitness to compete (AHA/ACC athlete statement) | At diagnosis and before returning to competition | Up to date | Not yet controlled; no bouts |
| Survey | Drinking (AUDIT-C, drinks per week, drinking days) | Every follow-up during treatment; full AUDIT at about four months | Completed today | AUDIT-C 7; about 15 drinks a week, with heavy Saturday nights |
| Laboratory | Liver tests (AST, ALT, GGT) | Baseline; about two months after starting naltrexone or cutting down; then as indicated | Ordered | Intake AST 46, ALT 38, GGT 88 U/L; recheck in about two months on naltrexone |
| Medication safety | Naltrexone: nausea, liver tests, and opioid-blockade wallet card | Each follow-up after starting | Completed today | Started today; no opioid use; wallet card given |
| Survey | Suicide-risk review (structured questions) and safety plan | Every visit | Completed today | No thoughts of suicide |
| Self-management | Health literacy: teach-back, picture card, read-aloud consent, voice reminders | Every visit | Completed today | Teach-back of the new dose and of naltrexone correct; voice-message readings set up |

## Goal progress

- Confirm or rule out hypertension with out-of-office readings before any medicine. Outcome by 2026-06-23: Ambulatory monitoring confirmed stage 2 hypertension (daytime 146/94 mmHg). **S**
- Blood pressure under 130/80 mmHg in the clinic and at home by four months. In progress; target 2026-10-20. **S**
- Drink within the goal he set: no more than 14 drinks a week and no more than 4 on any day, and none in the two weeks before a fight. In progress; target 2026-10-20. **S**
- Explain his medicines and blood pressure plan back in his own words. Outcome by 2026-07-21: Teach-back correct at four weeks with the picture card. **S**

## Medication changes

- Stopped: Amlodipine 5 mg and valsartan 160 mg combined oral tablet, one tablet each morning **S**
- Started: Amlodipine 10 mg and valsartan 160 mg combined oral tablet, one tablet each morning **S**
- Started: Naltrexone 50 mg oral tablet, one tablet each morning **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Circulation 2025;152(11):e114-e218)
- CMID: Clinical Monitoring Intelligence Database, hypertension and depression monographs (2026), Aether Forge
- The Healthcare Professional's Core Resource on Alcohol (2026), National Institute on Alcohol Abuse and Alcoholism
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (Am J Psychiatry 2018;175(1):86-90)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- AHRQ Health Literacy Universal Precautions Toolkit, 3rd Edition (2024), Agency for Healthcare Research and Quality

## Follow-up

- Preventive visit in three weeks. Three-month review in two months with liver tests and AUDIT-C. Call 988 or the clinic at any time if thoughts of suicide arise. **S**
- Next scheduled visit 2026-08-11: periodic adult preventive visit. **S**
